Literature DB >> 15160791

Multidetector pulmonary CT angiography: advances in the evaluation of pulmonary arterial diseases.

Maureen S Filipek1, Marc V Gosselin.   

Abstract

Multidetector CT (MDCT) has a primary role in the evaluation of pulmonary artery diseases. Contrast-enhanced MDCT studies are ideally suited for assessment of pulmonary arterial hypertension (PAH) and pulmonary thromboembolic disease. It has become the primary modality to diagnose acute and chronic thromboembolic disease. Its role in the evaluation of pulmonary hypertension is evolving, allowing the radiologist to assess the presence of disease and differentiating intrinsic versus extrinsic pulmonary arterial pathology. An understanding of pulmonary CT angiography, its appropriate application, associated pitfalls, contrast dynamics, and thin-section CT pulmonary and cardiac anatomy is necessary for accurate interpretation by the radiologist. In addition to assessing the pulmonary arteries MDCT has the implicit advantage of thin-section lung parenchymal imaging, a feature that often renders an alternative diagnosis when symptoms of pulmonary arterial disease occur.

Entities:  

Mesh:

Year:  2004        PMID: 15160791     DOI: 10.1016/j.sult.2003.12.003

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  2 in total

Review 1.  Chronic thromboembolic pulmonary hypertension - assessment by magnetic resonance imaging.

Authors:  Karl-Friedrich Kreitner; R Peter Kunz; Sebastian Ley; Katja Oberholzer; Daniel Neeb; Klaus K Gast; Claus-Peter Heussel; Balthasar Eberle; Eckhard Mayer; Hans-Ulrich Kauczor; Christoph Düber
Journal:  Eur Radiol       Date:  2006-07-13       Impact factor: 5.315

2.  Optimization of the scan protocol for the reduction of diaphragmatic motion artifacts depicted on CT angiography: a phantom study simulating pediatric patients with free breathing.

Authors:  Jee Hyun Baek; Whal Lee; Kee-Hyun Chang; Jin Wook Chung; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2009-04-22       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.